Chronic Kidney Disease

Marc Richards, MD, discusses how new therapies and combination treatment strategies are transforming evidence-based care for chronic kidney disease.

Michael Richards, MD, discusses aldosterone's role in CKD pathophysiology and why targeting this pathway may reshape kidney disease treatment.

MOTheR trial data suggest expanded hemodialysis offers comparable outcomes to online hemodiafiltration for dialysis patients, Patricia de Sequera, MD, PhD explains.

Catch up on some of the biggest FDA news, clinical trial updates, and featured HCPLive coverage from the first half of 2026.

Andrew Bzowyckyj, PharmD, explains the transition to the 2021 CKD-EPI equation and its implications for medication decisions.

FDA sends fresh CRL for Unicycive’s OLC; manufacturing inspection delays approval, while data support a lower pill-burden phosphate binder.

Katherine Tuttle, MD, discusses shifting the goals of chronic kidney disease management from slowing progression to preserving kidney function.

Butler explains why the urine albumin-to-creatinine ratio belongs in routine heart failure risk assessment and where the open questions remain.

New systematic review of 7012 kidney transplant recipients with T2D finds GLP-1 receptor agonists cut major adverse kidney events and mortality by 61%.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.

Phase 3 post hoc data linked lorundrostat to lower systolic blood pressure and albuminuria in patients with hypertension and CKD.

The FDA accepted Bayer’s sNDA for finerenone in adults with type 1 diabetes and CKD based on albuminuria data from FINE-ONE.

Data from a study deploying mobile health units across Detroit, Michigan, found CKD stage ≥3 rates double the national average and increased rates in at-risk subgroups.

Pranav discusses the necessity for addressing the structural barriers that remain for living donor kidney transplantations in black patients.

Davies explains the future of at-home dialysis access, including policy changes and technological innovation.

Catch up on nephrology headlines you missed from Q1 2026.

Davies breaks down the gaps to at-home dialysis access and the future of global collaboration.

HCPLive’s editorial team has compiled 5 of the most informative discussions, along with key data from the WCN.

An expert shares his perspective on emerging targets and precision strategies for podocyte injury in glomerular disease.

Catch up on the guideline updates, trial news, and featured content from March 2026.

Nicholls discusses the investigational oral CETP inhibitor’s effects on kidney health for patients at high risk of cardiovascular disease due to elevated HDL-C.

The WHO resolution on kidney health elevates kidney disease as a global health priority, emphasizing early detection, treatment, and system-wide action.

Further CONFIDENCE analyses support safe combination therapy in CKD, with improved responses in key patient subgroups.

New OPTN data shows kidney transplant gains from race-free GFR and restored wait times stall, as structural barriers still limit equitable listing access.

Chan describes the current landscape of dialysis care and why home-based approaches are gaining momentum for patients with ESRD.